All filters
Slidesets
Modulation of gut microbiota by indoleamine 2,3-dioxygenase 1 inhibitor during antiretroviral suppressed SIV infection in rhesus macaques- Zhang Wang
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
Effect of high-risk sexual behaviouron diversity of the vaginal microbiota and abundance of lactobacillus- Jocelyn Wessels
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
Identification of rapid and emerging transmission clusters from genetic network- Tsz Ho Kwa
Presented at:
International Workshop on HIV Transmission 2017
Slidesets
Vaccine induced susceptibility vs protection- Roger Legrand
Presented at:
International Workshop on HIV Transmission 2017
Slidesets
Phylogenetic, epidemiological and virological insights on the rise of large cluster outbreaks fueling the HIV-1 epidemic among Men having sex with Men within Quebec-Bluma Brenner
Presented at:
International Workshop on HIV Transmission 2017
Slidesets
Making PrEP a succes- Annemarie Wensing, MD, PhD
Presented at:
International Workshop on HIV Transmission 2017
Slidesets
Behaviour perspective- Ian McGowan, MB, ChB, DPhil, MD, FRCP
Presented at:
International Workshop on HIV Transmission 2017
Slidesets
HIV-1 Vif adaptation to host immune pressure impact of cytidine deaminases and host HLA- Nicole Reddy
Presented at:
International Workshop on HIV Transmission 2017
Slidesets
Trafficking of HIV out of the mucosa- Claudia Cicala, PhD
Presented at:
International Workshop on HIV Transmission 2017
Slidesets
Introduction: Using transmission networks for targeted interventions- Charles Boucher, MD, PhD
Presented at:
International Workshop on HIV Transmission 2017
Slidesets
Transmitted drug-resistance in newly diagnosed HIV drug-naïve individuals in Portugal- Marta Sofia Pingarilho
Presented at:
International Workshop on HIV Transmission 2017
Slidesets
Current and Future Treatment of CMV- Robin Avery, MD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_1: Single- and multiple-ascending doses (SAD/MAD) and food effect of orally administered JNJ-64155806 in healthy volunteers- Thomas Kakuda, PharmD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_2: Effects of cobicistat on tenofovir durability: is it time to rethink at TAF trials?- Dario Cattaneo, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_4: Evaluation of the Drug-Drug Interaction Potential between Cobicistat-Boosted Protease Inhibitors and Statins - Dr Joseph Custodio
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_5: Confirmation of the drug-drug interaction (DDI) potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives- Dr Sophia Majeed
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_3: Pharmacokinetics of darunavir/cobicistat and etravirine alone and coadministered in HIV-infected patients- José Moltó, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_6: Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir- Catia Marzolini, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
Current Challenges in Pediatric Drug Development- Robert Ward, MD, FAAP, FCP
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
Clinical Aspects of Pediatric Treatment- Tim Cressey, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_8: Relationship between dolutegravir plasma exposure, quality of sleep and its functional outcome in patients living with HIV over the age of 60 years.- Marta Boffito, MD, PhD, FRCP
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_7: A Comparison of the Pharmacokinetics of Dolutegravir during Pregnancy and Postpartum- Dr Pauline Bollen
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017